home · filing · 0001193125-23-221586
8-K filed August 25, 2023, 7:59 PM ET
ticker DSGN
CIK 0001807120
leadership
confidence high
sentiment neutral
materiality 0.55
Design Therapeutics CEO Siffert resigns; Chair Shah appointed CEO, receives stock options
Design Therapeutics, Inc.
João Siffert resigned as President/CEO/principal financial officer effective Aug 25, 2023; employee status ends Sept 1, 2023.
Pratik Shah, Ph.D., Board Chair, appointed President, CEO and principal financial officer effective Aug 25, 2023; Simeon George named lead independent director.
Siffert receives 12-month salary continuation, $230,220 prorated bonus, 12-month COBRA, extended option exercisability (6 months).
Shah granted options: 1,050,000 shares time-vesting; 525,000 shares contingent on FA IND clearance; 525,000 shares contingent on FA Phase 2a start.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Departed
João Siffert
President, Chief Executive Officer and principal financial officer
DSGN ·
Design Therapeutics, Inc.
Effective 2023-08-25
Successor Pratik Shah
Filed August 25, 2023, 7:59 PM ET
agreed to the resignation of Dr. Siffert from all offices of the Company and from the Board, effective immediately
Appointed
Pratik Shah
President, Chief Executive Officer and principal financial officer
DSGN ·
Design Therapeutics, Inc.
Effective 2023-08-25
Filed August 25, 2023, 7:59 PM ET
On August 25, 2023, the Board appointed Pratik Shah, Ph.D., as the Company’s President, Chief Executive Officer and principal financial officer.
Effective 2023-08-25
Filed August 25, 2023, 7:59 PM ET
the Board appointed Simeon George, M.D., as the Company’s lead independent director
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
João Siffert resigned as President, Chief Executive Officer and principal financial officer at Design Therapeutics, Inc..
Action resigned
Role President, Chief Executive Officer and principal financial officer
Exact text from the filing
agreed to the resignation of Dr. Siffert from all offices of the Company and from the Board, effective immediately
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Pratik Shah was appointed as President, Chief Executive Officer and principal financial officer at Design Therapeutics, Inc..
Action appointed
Role President, Chief Executive Officer and principal financial officer
Exact text from the filing
On August 25, 2023, the Board appointed Pratik Shah, Ph.D., as the Company’s President, Chief Executive Officer and principal financial officer.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Simeon George was appointed as Lead Independent Director at Design Therapeutics, Inc..
Action appointed
Role Lead Independent Director
Exact text from the filing
the Board appointed Simeon George, M.D., as the Company’s lead independent director
View on SEC.gov
Source: SEC EDGAR
accession 0001193125-23-221586
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.